PlasmaSELECT™-R64 analyzes circulating
tumor DNA for genetic alterations in cancer, eliminating the need for an
invasive biopsy or tumor tissue. PlasmaSELECT™-R may also be used to evaluate sub-clonal mutations in tumor tissue, when available. PlasmaSELECT™-R evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations, microsatellite instability (MSI) and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations or rearrangements can be performed together or separately, depending on the specific alterations of interest.